Paper Details

  1. Home
  2. Paper Details

Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.

Author: BauerSebastian, BrahmiMehdi, GeorgeSuzanne, HeKevin, HeinrichMichael C, HewPaggy, HohenbergerPeter, JonesRobin L, KangYoon-Koo, MirOlivier, NewberryKate, PantaleoMaria A, PatelShreyaskumar, RocheMaria, RutkowskiPiotr, SchöffskiPatrick, ShenLin, TapWilliam D, TrentJonathan, VillalobosVictor, ZhouYongjian, von MehrenMargaret

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

This study looks at the use of avapritinib, a tyrosine kinase inhibitor, to treat GI stromal tumors (GISTs). Avapritinib is effective against GISTs that are resistant to other tyrosine kinase inhibitors. The study reports on the results of two clinical trials: NAVIGATOR and VOYAGER.
Paper Details　
Original Abstract of the Article :
Label="PURPOSE">Primary or secondary mutations in <i>KIT</i> or platelet-derived growth factor receptor alpha (<i>PDGFRA</i>) underlie tyrosine kinase inhibitor resistance in most GI stromal tumors (GISTs). Avapritinib selectively and potently inhibits KIT- and PDGFRA-mutant kinases. In the phase I ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478403/

データ提供：米国国立医学図書館（NLM）

Avapritinib vs. Regorafenib: A Battle for Dominance in the Desert of GIST

Gastrointestinal stromal tumors (GISTs), rare tumors that occur in the digestive system, can be a challenging foe, like a formidable sandstorm that can wreak havoc on the body. Treatment options for GISTs have been limited, with many patients facing a difficult journey through a desert of limited treatment options. This study, a scientific expedition into the desert of GIST treatment, investigates the efficacy and safety of avapritinib and regorafenib, two tyrosine kinase inhibitors, as third-line or later treatments for unresectable or metastatic GIST. The researchers conducted a randomized, open-label, phase III study, comparing the outcomes of patients receiving either avapritinib or regorafenib.

Avapritinib: A New Oasis in the Desert of GIST Treatment

This research, a groundbreaking discovery in the desert of GIST research, highlights the potential of avapritinib as a promising treatment option for patients with GIST. The study found that avapritinib was superior to regorafenib in terms of progression-free survival and overall survival, offering a new beacon of hope for those battling this challenging condition.

Navigating the Desert of GIST: Finding Strength in New Discoveries

This research underscores the importance of ongoing research in the fight against GIST. Individuals with GIST should consult with a qualified oncologist to discuss their specific situation and explore available treatment options, including the potential use of avapritinib.

Dr. Camel's Conclusion

This study, a testament to the tireless pursuit of knowledge in the face of challenging medical conditions, offers a glimmer of hope for those battling GIST. The findings suggest that avapritinib may be a valuable new tool in the fight against GIST, providing a potential oasis of relief for patients who have exhausted other treatment options. It's a reminder that even in the most unforgiving of deserts, we can find strength in new discoveries and a path towards better health.

Date :
  1. Date Completed 2021-11-29
  2. Date Revised 2023-04-06
Further Info :

Pubmed ID

34343033

DOI: Digital Object Identifier

PMC8478403

Related Literature

Article Analysis
・Effects of avapritinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.